87 related articles for article (PubMed ID: 22780906)
1. Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer.
Chitkara D; Singh S; Kumar V; Danquah M; Behrman SW; Kumar N; Mahato RI
Mol Pharm; 2012 Aug; 9(8):2350-7. PubMed ID: 22780906
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Almawash SA; Mondal G; Mahato RI
Pharm Res; 2018 Jan; 35(1):17. PubMed ID: 29305793
[TBL] [Abstract][Full Text] [Related]
3. Copolymeric micelles for delivery of EGCG and cyclopamine to pancreatic cancer cells.
Sun L; Zhang C; Li P
Nutr Cancer; 2014; 66(5):896-903. PubMed ID: 24798568
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
5. Chemoradiation therapy using cyclopamine-loaded liquid-lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles.
You J; Zhao J; Wen X; Wu C; Huang Q; Guan F; Wu R; Liang D; Li C
J Control Release; 2015 Mar; 202():40-8. PubMed ID: 25637565
[TBL] [Abstract][Full Text] [Related]
6. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.
Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI
Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells.
Hu K; Zhou H; Liu Y; Liu Z; Liu J; Tang J; Li J; Zhang J; Sheng W; Zhao Y; Wu Y; Chen C
Nanoscale; 2015 May; 7(18):8607-18. PubMed ID: 25898852
[TBL] [Abstract][Full Text] [Related]
8. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells.
Hu WG; Liu T; Xiong JX; Wang CY
Acta Pharmacol Sin; 2007 Aug; 28(8):1224-30. PubMed ID: 17640486
[TBL] [Abstract][Full Text] [Related]
9. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
Zhou X; Zheng M; Chen F; Zhu Y; Yong W; Lin H; Sun Y; Han X
Anat Rec (Hoboken); 2009 Aug; 292(8):1122-7. PubMed ID: 19645012
[TBL] [Abstract][Full Text] [Related]
12. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Mimeault M; Mehta PP; Hauke R; Henichart JP; Depreux P; Lin MF; Batra SK
Growth Factors; 2007 Dec; 25(6):400-16. PubMed ID: 18365871
[TBL] [Abstract][Full Text] [Related]
13. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy.
Mohanty C; Acharya S; Mohanty AK; Dilnawaz F; Sahoo SK
Nanomedicine (Lond); 2010 Apr; 5(3):433-49. PubMed ID: 20394536
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer.
Gao X; Wang B; Wei X; Men K; Zheng F; Zhou Y; Zheng Y; Gou M; Huang M; Guo G; Huang N; Qian Z; Wei Y
Nanoscale; 2012 Nov; 4(22):7021-30. PubMed ID: 23044718
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model.
Sui G; Bonde P; Dhara S; Broor A; Wang J; Marti G; Feldmann G; Duncan M; Montgomery E; Maitra A; Harmon JW
J Surg Res; 2006 Jul; 134(1):1-9. PubMed ID: 16488438
[TBL] [Abstract][Full Text] [Related]
16. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
Wang C; Yang A; Zhang B; Yin Q; Huang H; Chen M; Xie J
Pancreas; 2014 Mar; 43(2):291-7. PubMed ID: 24518510
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer.
Yang R; Mondal G; Wen D; Mahato RI
Nanomedicine; 2017 Feb; 13(2):391-401. PubMed ID: 27520724
[TBL] [Abstract][Full Text] [Related]
18. The anti-tumor efficacy of curcumin when delivered by size/charge-changing multistage polymeric micelles based on amphiphilic poly(β-amino ester) derivates.
Yu Y; Zhang X; Qiu L
Biomaterials; 2014 Mar; 35(10):3467-79. PubMed ID: 24439418
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
20. Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer.
Zhang B; Jiang T; Shen S; She X; Tuo Y; Hu Y; Pang Z; Jiang X
Biomaterials; 2016 Oct; 103():12-21. PubMed ID: 27376555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
